Title (60 chars): Eris Lifesciences Q1 FY27: GLP-1 leader

Eris Lifesciences Limited reported Q1 FY27 results for the June 2026 quarter on 29 July. Revenue grew 13% and profit 14.5%, but the EBITDA margin missed guidance. Q1 FY27 numbers (consolidated): Revenue: Rs 873.25 crore, up 13% YoY from Rs 771.56 crore EBITDA: Rs 296 crore, up 7% YoY; margin 33.9% vs FY27 guidance 36 to 37% PAT: Rs 142.39 crore, up 14.5% YoY from Rs 125.10 crore; EPS Rs 10.28 DBF segment: up 14.2%; 7 of 10 therapies in double digits Semaglutide (GLP-1): 20% volume share, 14% value share; ranked first in generic semaglutide prescriptions Interim dividend Rs 7.21 per share The margin miss is structural. Biologics and insulin carry lower initial gross margins than legacy oral anti-diabetes; as they scale, margins are expected to recover. HALMED inspection findings from March 2026 have delayed European CDMO commercialisation. Eris Lifesciences [][***** shares closed at Rs 1,288.21 (18 Sep 2026, 03:29 PM IST), down 23 percent over one year, near the Rs 1,222 52-week low. P/E 27.6; sector P/E 44.64; PEG 0.38. My view: the GLP-1 thesis is intact — number-one rank in generic semaglutide prescriptions in the launch quarter. The issue is that biologics compress margins in the near term and HALMED delays the EU CDMO revenue that was part of the FY27 thesis. At 27.6x, PEG 0.38 vs sector 44x, the compressed multiple is either an opportunity or an early signal of structural margin pressure. FY27 margin exit rate is the test. Accumulate Rs 1,222 to 1,290; invalidation on a close below Rs 1,222; Rs 1,450 to 1,500 the resistance. Disclosure: Vijay Kumar Gupta, SEBI Registered Research Analyst, INH000020226, Vijay Gupta Advisory. SEBI registration and NISM certification do not guarantee performance or assure returns. Securities markets are subject to market risks. No holdings in the subject company.